Abstract
Advances in genomic analyses enable the identification of
new proteins that are associated with disease. To validate these targets, tool
molecules are required to demonstrate that a ligand can have a
disease-modifying effect. Currently, as tools are reported for only a fraction
of the proteome, platforms for ligand discovery are essential to leverage
insights from genomic analyses. Fragment screening offers an efficient approach
to explore chemical space, however, it remains challenging to develop techniques
that are both sufficiently high-throughput and sensitive. We present a fragment
screening platform, termed PhABits (PhotoAffinity Bits), which utilises a
library of photoreactive fragments to covalently capture fragment-protein
interactions. Hits can be profiled to determine potency and site of
crosslinking, and subsequently developed as reporters in a competitive
displacement assay to identify novel hit matter. We envision that the PhABits
will be widely applicable to novel protein targets, identifying starting points
in the development of therapeutics.